Cara Therapeutics (CARA) Competitors $4.63 -0.15 (-3.14%) Closing price 04:00 PM EasternExtended Trading$4.65 +0.02 (+0.43%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CARA vs. ARTV, HLVX, VOR, SKYE, DBVT, CTOR, ALTS, MGX, RANI, and ORMPShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Artiva Biotherapeutics (ARTV), HilleVax (HLVX), Vor Biopharma (VOR), Skye Bioscience (SKYE), DBV Technologies (DBVT), Citius Oncology (CTOR), Janone (ALTS), Metagenomi (MGX), Rani Therapeutics (RANI), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. Artiva Biotherapeutics HilleVax Vor Biopharma Skye Bioscience DBV Technologies Citius Oncology Janone Metagenomi Rani Therapeutics Oramed Pharmaceuticals Artiva Biotherapeutics (NASDAQ:ARTV) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Do insiders & institutionals have more ownership in ARTV or CARA? 44.7% of Cara Therapeutics shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer ARTV or CARA? Cara Therapeutics received 658 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 72.50% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformArtiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesCara TherapeuticsOutperform Votes66772.50% Underperform Votes25327.50% Which has higher earnings and valuation, ARTV or CARA? Artiva Biotherapeutics has higher earnings, but lower revenue than Cara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$2.60M36.61N/AN/AN/ACara Therapeutics$8.69M2.44-$118.51M-$21.01-0.22 Do analysts rate ARTV or CARA? Artiva Biotherapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 435.71%. Cara Therapeutics has a consensus price target of $27.84, suggesting a potential upside of 501.30%. Given Cara Therapeutics' higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ARTV or CARA more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Artiva Biotherapeutics' return on equity of 0.00% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A N/A N/A Cara Therapeutics -1,099.76%-367.97%-107.43% Does the media prefer ARTV or CARA? In the previous week, Artiva Biotherapeutics and Artiva Biotherapeutics both had 1 articles in the media. Artiva Biotherapeutics' average media sentiment score of 1.87 equaled Cara Therapeutics'average media sentiment score. Company Overall Sentiment Artiva Biotherapeutics Very Positive Cara Therapeutics Very Positive SummaryArtiva Biotherapeutics beats Cara Therapeutics on 7 of the 12 factors compared between the two stocks. Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARA vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.16M$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-0.226.1524.9519.24Price / Sales2.44187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book0.376.447.334.28Net Income-$118.51M$139.03M$3.18B$247.04M7 Day Performance-7.58%-5.52%-4.42%-4.36%1 Month Performance-3.14%-8.56%-6.07%-5.60%1 Year Performance-59.39%-14.59%11.42%3.38% Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARACara Therapeutics3.9153 of 5 stars$4.63-3.1%$27.84+501.3%-58.1%$21.16M$8.69M-0.2280Positive NewsARTVArtiva BiotherapeuticsN/A$3.77flat$21.00+457.0%N/A$91.57MN/A0.0081Positive NewsHLVXHilleVax2.6162 of 5 stars$1.83flat$3.00+63.9%-90.6%$91.15MN/A-0.5920Positive NewsVORVor Biopharma2.5737 of 5 stars$1.32-3.6%$11.36+760.4%-52.4%$90.64MN/A-0.80140News CoverageSKYESkye Bioscience1.0124 of 5 stars$2.87+5.2%$18.67+549.7%-83.0%$90.41MN/A0.0011Analyst ForecastGap UpDBVTDBV Technologies3.1714 of 5 stars$4.38-0.4%$22.50+413.2%-46.4%$90.17M$15.73M-0.9780Gap DownCTORCitius OncologyN/A$1.25+6.8%$3.00+140.0%N/A$89.44MN/A0.00N/APositive NewsGap DownALTSJanoneN/A$6.21-5.9%N/AN/A$87.37M$7.11M0.00170Short Interest ↑News CoverageMGXMetagenomi2.1809 of 5 stars$2.33-1.3%$16.67+615.3%-82.9%$87.19M$44.76M0.00236Positive NewsRANIRani Therapeutics3.1597 of 5 stars$1.52-8.4%$12.33+711.4%-58.5%$87.08MN/A-1.43110Short Interest ↑Positive NewsORMPOramed Pharmaceuticals1.2533 of 5 stars$2.16+0.5%N/A-38.9%$87.07M$1.34M19.6410Short Interest ↑ Related Companies and Tools Related Companies Artiva Biotherapeutics Competitors HilleVax Competitors Vor Biopharma Competitors Skye Bioscience Competitors DBV Technologies Competitors Citius Oncology Competitors Janone Competitors Metagenomi Competitors Rani Therapeutics Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CARA) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
